AstraZeneca is to stop research into 10 diseases to cut costsBMJ 2010; 340 doi: https://doi.org/10.1136/bmj.c1365 (Published 08 March 2010) Cite this as: BMJ 2010;340:c1365
- Andrew Jack
- 1Financial Times
AstraZeneca, the Anglo-Swedish pharmaceutical group, is to reduce its staff, shut operations, and cease research into several diseases as part of a wide ranging restructuring, unveiled at the start of March.
The company will close some research centres in the United Kingdom, Sweden, and the United States and is set to cut 3500 posts in research and development by 2014. When new jobs are taken into account, the net loss of jobs is likely to be 1800.
It will stop all future research into 10 diseases, including acid reflux, schizophrenia, and bipolar disorder, which represent some of the company’s …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial